Chemosensitivity of human pancreatic carcinoma cells is enhanced by IκBα super-repressor

Cancer Science

Volumn 94, Issue 5, 2003, Pages 467-472

  Sato, Toshiyuki ^a   Odagiri, Hiroki ^a   Ikenaga, Shojiro Kazunori ^a   Maruyama, Masateru ^a   Sasaki, Mutsuo ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; DOXORUBICIN; ETOPOSIDE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN MDM2;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA MICROARRAY; DRUG RESISTANCE; DRUG SENSITIVITY; FEASIBILITY STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REPRESSOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELLS, CULTURED; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION PROFILING; HUMANS; I-KAPPA B PROTEINS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; TRANSFECTION;

EID: 0037743875     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01466.x     Document Type: Article

References (29)

1. Matsuno M. Multi-institutional registration and follow-up studies of patients with pancreatic cancer throughout the country (Summary of cases in 1999). J Jpn Pancreas Soc 2001; 16: 115-47.
2. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-84.
3. Neoptolemos JP, Baker P, Beger H, Link K, Pederzoli P, Bassi C, Dervenis C, Friess H, Buchler M. Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in respectable pancreatic cancer (ESPAC-1). Int J Pancreatol 1997; 21: 91-104.
4. Shinoura N, Yamamoto N, Yoshida Y, Fujita T, Saito N, Asai A, Kirino T, Hamada H. Adenovirus-mediated gene transduction of IκB or IκB plus Bax gene drastically enhances tumor necrosis factor (TNF)-induced apoptosis in human gliomas. Jpn J Cancer Res 2000; 91: 41-51.
5. Wang CY, Cusack JC Jr, Liu R, Baldwin A Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999; 5: 412-7.
6. Arlt A, Vorndamm J, Breitenbrouch M, Folsh UR, Kalthoff H, Schmidt WE, Schafer H. Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001; 20: 859-68.
7. Feig BW, Lu X, Hunt KK, Shan Q, Yu D, Pollock R, Chiao P. Inhibition of transcription factor nuclear factor-κ B by adenoviral-mediated expression of IκBαM results in tumor cell death. Surgery 1999; 126: 399-405.
8. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ, Sledge GW, Nakshatri H. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 2000; 19: 4159-69.
9. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNFα-induced apoptosis by NF-κB. Science 1996; 274: 787-9.
10. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996; 274: 784-7.
11. Bentires-Alj M, Hellin AC, Ameyar M, Chouaib S, Merville MP, Bours V. Stable inhibition of nuclear factor κB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res 1999; 59: 811-5.
12. Tietze MK, Wuestefeld T, Paul Y, Zender L, Trautwein C, Manns MP, Kubicka S. IκBα gene therapy in tumor necrosis factor α- and chemotherapy-mediated apoptosis of hepatocellular carcinomas. Cancer Gene Ther 2000; 7: 1315-23.
13. Cai Z, Korner M, Tarantino N, Chouaib S. κBα over-expression in human breast carcinoma MCF7 cells inhibits nuclear factor-κB activation but not tumor necrosis factor α-induced apoptosis. J Biol Chem 1997; 272: 96-101.
14. Li Y, Zhang W, Mantell LL, Kazzaz JA, Fein AM, Horowitz S. Nuclear factor-κB is activated by hyperoxia but does not protect from cell death. J Biol Chem 1997; 272: 21646-9.
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
16. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNFα-induced cell death. Science 1996; 274: 782-4.
17. Sheper RJ, Broxterman HJ, Sheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53: 1475-9.
18. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-10.
19. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deelwy RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54: 357-61.
20. Muller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, Mulder NH, de Vries ED, Jansen PL. Overexpression of gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 1994; 91: 13033-7.
21. Sceffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995; 1: 578-82.
22. Kudoh K, Ramanna M, Racatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS, Chin KV. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 2000; 60: 4161-6.
23. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, Tamaoki N, Nomura T, Kitahara O, Yanagawa R, Hirata K, Nakamura Y. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human colon cancer xenografts to anticancer drugs. Cancer Res 2000; 62: 518-27.
24. Hochhauser D, Valkov, Gump JL, Wei I, O'Hare C, Hartley J, Fan J, Bertino JR, Banerjee D, Sullivan DM. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIα and β in various human cancer cell lines. J Cell Biochem 1999; 75: 245-57.
25. Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53 dependent G1 arrest. Proc Natl Acad Sci USA 1996; 93: 4827-32.
26. Ikeguchi M, Ueda T, Fukuda K, Yamaguchi K, Tsujitani S, Kaibara N. Expression of murine double minute gene 2 oncoprotein in esophageal squamous cell carcinoma as a novel marker for lack of response to chemoradiotreatment. Am J Clin Oncol 2002; 25: 454-9.
27. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. p53 stabilization is decreased upon NF-κB activation: a role for NF-κB in acquisition of resistance to chemotherapy. Cancer Cell 2002; 1: 493-503.
28. Gu L, Findley HW, Zhou M. MDM2 induces NF-κB/p65 expression transcriptionally through Spl-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 2002; 99: 3367-75.
29. Randolph J, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabin in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555-61.